Ranked #1,014 of 8,699 institutional investors
Vestal Point Capital, LP
New York, NY
$3.56B
US stock portfolio at live prices · today −$57.0M (−1.58%)
Live prices, last trade 11:13 AM ET
- Value at quarter end (Q3 2026)
- $3.87B
- Change from Q2 2026
- −$408.7M (−9.55%)
- Positions
- 56 · 13 new, 16 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$329M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesINSM 11.2%NBIX 10.8%BMRN 9.50%ABVX 7.86%UTHR 7.39%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| INSM Insmed Incorporated | 2,725,000 | $400M | 11.2% | Added +990% |
| NBIX Neurocrine Biosciences, Inc. | 2,500,000 | $385M | 10.8% | Added +33% |
| BMRN BioMarin Pharmaceutical Inc. | 5,525,000 | $338M | 9.50% | Reduced −8% |
| ABVX ABIVAX Société Anonyme | 3,960,000 | $280M | 7.86% | Added +69% |
| UTHR United Therapeutics Corporation | 475,000 | $263M | 7.39% | Added +9% |
| ARWR Arrowhead Pharmaceuticals, Inc. | 4,815,000 | $207M | 5.82% | Added +206% |
| TARS Tarsus Pharmaceuticals, Inc. | 2,033,625 | $153M | 4.29% | Added +94% |
| ELVN Enliven Therapeutics, Inc. | 3,225,000 | $152M | 4.26% | Reduced −19% |
| IRON Disc Medicine, Inc. | 1,635,000 | $122M | 3.43% | Added +5% |
| DYN Dyne Therapeutics, Inc. | 6,200,000 | $99.5M | 2.79% | Added +84% |
| NRIX Nurix Therapeutics, Inc. | 7,025,000 | $93.2M | 2.62% | Reduced −13% |
| TSHA Taysha Gene Therapies, Inc. | 18,045,000 | $68.0M | 1.91% | Reduced −7% |
| GMED Globus Medical, Inc. | 915,000 | $62.3M | 1.75% | Added +8% |
| GLUE Monte Rosa Therapeutics, Inc. | 7,130,000 | $62.2M | 1.75% | Added +55% |
| BCAX Bicara Therapeutics Inc. | 5,525,000 | $49.7M | 1.40% | Added +5% |
| ZBH Zimmer Biomet Holdings, Inc. | 475,000 | $48.5M | 1.36% | Reduced −66% |
| XENE Xenon Pharmaceuticals Inc. | 850,000 | $31.8M | 0.89% | Added +21% |
| BBIO BridgeBio Pharma, Inc. | 400,000 | $30.9M | 0.87% | New |
| TVTX Travere Therapeutics, Inc. | 600,000 | $29.0M | 0.81% | New |
| PODD Insulet Corporation | 175,000 | $24.4M | 0.68% | Reduced −74% |
| SNY Sanofi | 500,000 | $23.3M | 0.65% | Reduced −75% |
| IMCR Immunocore Holdings plc | 850,000 | $22.6M | 0.64% | Reduced −53% |
| RCUS Arcus Biosciences, Inc. | 1,300,000 | $20.9M | 0.59% | New |
| TRVI Trevi Therapeutics, Inc. | 1,495,000 | $20.1M | 0.56% | Reduced −52% |
| SGP SpyGlass Pharma, Inc. | 640,000 | $20.0M | 0.56% | Reduced −4% |
| ZYME Zymeworks Inc. | 600,000 | $16.4M | 0.46% | New |
| NKTR Nektar Therapeutics | 510,000 | $16.1M | 0.45% | Reduced −49% |
| SVRA Savara Inc. | 3,300,000 | $14.2M | 0.40% | Added +21% |
| LXEO Lexeo Therapeutics, Inc. | 4,320,000 | $13.6M | 0.38% | Unchanged |
| SLDB Solid Biosciences Inc. | 2,085,000 | $13.3M | 0.37% | Reduced −3% |
| COGT Cogent Biosciences, Inc. | 475,000 | $12.9M | 0.36% | New |
| DRUG Bright Minds Biosciences Inc. | 545,000 | $11.6M | 0.32% | Unchanged |
| GKOS Glaukos Corporation | 45,000 | $10.8M | 0.30% | New |
| ZBIO Zenas BioPharma, Inc. | 395,000 | $10.1M | 0.28% | Added +8% |
| KRSA Korsana Biosciences, Inc. | 263,105 | $9.9M | 0.28% | New |
| STOK Stoke Therapeutics, Inc. | 345,000 | $9.4M | 0.27% | New |
| EVMN Evommune Inc | 1,250,000 | $8.8M | 0.25% | Added +25% |
| TECX Tectonic Therapeutic, Inc. | 360,000 | $7.6M | 0.21% | Reduced −15% |
| VKTX Viking Therapeutics, Inc. | 290,000 | $7.4M | 0.21% | Reduced −57% |
| KLRA Kailera Therapeutics, Inc. | 625,000 | $7.3M | 0.20% | Added +9% |
| TRAX First Tracks Biotherapeutics, Inc. | 169,738 | $7.1M | 0.20% | Reduced −83% |
| RZLT Rezolute, Inc. | 1,455,000 | $5.8M | 0.16% | Added +280% |
| MLTX MoonLake Immunotherapeutics | 525,000 | $5.8M | 0.16% | New |
| MAZE Maze Therapeutics, Inc. | 175,000 | $5.7M | 0.16% | New |
| AVTX Avalo Therapeutics, Inc. | 800,000 | $5.5M | 0.15% | Added +3% |
| AVR Anteris Technologies Global Corp. | 850,000 | $4.3M | 0.12% | Reduced −16% |
| VYGR Voyager Therapeutics, Inc. | 2,165,000 | $3.5M | <0.1% | Reduced −18% |
| OLMA Olema Oncology, Inc. | 420,000 | $3.0M | <0.1% | Added +0% |
| OKUR OnKure Therapeutics, Inc. | 1,088,000 | $3.0M | <0.1% | Reduced −40% |
| ENGN enGene Therapeutics Inc. | 1,665,000 | $3.0M | <0.1% | Reduced −0% |
| NGNE Neurogene Inc. | 115,000 | $2.6M | <0.1% | New |
| PALI Palisade Bio, Inc. | 2,500,000 | $2.4M | <0.1% | Unchanged |
| IBIO iBio, Inc. | 2,600,000 | $2.1M | <0.1% | Unchanged |
| AVBP ArriVent BioPharma, Inc. | 100,000 | $1.1M | <0.1% | New |
| CTMX CytomX Therapeutics, Inc. | 535,000 | $1.1M | <0.1% | New |
| APRE Aprea Therapeutics, Inc. | 350,000 | $96K | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| ABT Abbott Laboratories | 1,400,000 | $146M |
| RVMD Revolution Medicines, Inc. | 450,000 | $74.5M |
| RGEN Repligen Corporation | 400,000 | $66.9M |
| BCRX BioCryst Pharmaceuticals, Inc. | 8,300,000 | $60.8M |
| BMY Bristol-Myers Squibb Company | 800,000 | $47.4M |
| REGN Regeneron Pharmaceuticals, Inc. | 40,000 | $37.3M |
| GEHC GE HealthCare Technologies Inc. | 450,000 | $36.7M |
| MYGN Myriad Genetics, Inc. | 5,735,000 | $31.6M |
| MDGL Madrigal Pharmaceuticals, Inc. | 65,000 | $25.4M |
| BBNX Beta Bionics, Inc. | 1,600,000 | $21.9M |
| ANRO Alto Neuroscience Inc | 785,000 | $19.9M |
| RAPP Rapport Therapeutics, Inc. | 730,000 | $17.2M |
| SRZN Surrozen, Inc. | 304,669 | $9.1M |
| MNPR Monopar Therapeutics Inc. | 75,727 | $5.2M |
| SGMT Sagimet Biosciences Inc. | 535,452 | $4.9M |
| TENX Tenax Therapeutics, Inc. | 53,439 | $69K |